Please login to the form below

Not currently logged in
Email:
Password:

OPKO appoints vice president of medical affairs

Dr Douglass Laidlaw brings experience from Relypsa and Sanofi

OPKO Health Dr Douglass LaidlawMiami-based OPKO Health has appointed Dr Douglass Laidlaw as vice president of medical affairs.

In his new role, Dr Laidlaw will be particularly responsible for overseeing the anticipated launch of the healthcare company's product Rayaldee.

Dr Laidlaw has over 15 years of experience in leading strategic planning, development and execution of medical education initiatives for numerous pharmaceutical companies, which include Genzyme, Keryx, Neurocine Biosciences and Serono.

He previously served as Relypsa's executive director, medical affairs and Sanofi's national director for medical science liasons, medical affairs.

Philip Frost, chairman and chief executive of OPKO, said: “Doug is a key addition to the management team in OPKO's renal division.

“A well-conceived and executed medical education strategy is critical to Rayaldee's acceptance by US healthcare professionals.”

6th June 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics